Motilal Oswal is bullish on Fortis Healthcare has recommended Buy rating on the stock with a target price of Rs 185 in its research report dated March 01, 2018.
Motilal Oswal's research report on Fortis Healthcare
Fortis Healthcare (FORH) reported 2QFY18/3QFY18 revenue of INR12b (flat YoY)/INR11.2b (-1.1% YoY), with EBIDTA margin of 8.9%/4.6%. Hospital business revenue came in at INR9.7b (-0.6% YoY)/INR9b (-0.9% YoY) for 2QFY18/3QFY18, with EBITDA margin of 8.5%/5.5%. SRL reported revenue of INR2.2b (+5.2% YoY)/INR2.1b (+10% YoY), with EBITDA margin of 23.2%/18.4%. 2Q numbers were in line, but 3Q numbers missed our expectations. FORH reported a loss of INR236m/INR191m in 2Q/3QFY18.
OutlookWe have valued the hospital and diagnostic business based on 20x and 18x 1HFY20E EV/EBITDA, respectively. We cut EBITDA by 26%/9% for FY19/20E as we build in slower margin ramp-up.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.